AU1832197A - Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts - Google Patents

Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts

Info

Publication number
AU1832197A
AU1832197A AU18321/97A AU1832197A AU1832197A AU 1832197 A AU1832197 A AU 1832197A AU 18321/97 A AU18321/97 A AU 18321/97A AU 1832197 A AU1832197 A AU 1832197A AU 1832197 A AU1832197 A AU 1832197A
Authority
AU
Australia
Prior art keywords
atherosclerosis
prevention
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18321/97A
Inventor
Thomas E. Fleming
Herbert C. Mansmann Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fleming and Co Pharmaceuticals
Original Assignee
Fleming & Co Pharmaceutic
Fleming and Co Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fleming & Co Pharmaceutic, Fleming and Co Pharmaceuticals filed Critical Fleming & Co Pharmaceutic
Publication of AU1832197A publication Critical patent/AU1832197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU18321/97A 1996-01-18 1997-01-17 Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts Abandoned AU1832197A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58856496A 1996-01-18 1996-01-18
US588564 1996-01-18
PCT/US1997/000821 WO1997025959A2 (en) 1996-01-18 1997-01-17 Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts

Publications (1)

Publication Number Publication Date
AU1832197A true AU1832197A (en) 1997-08-11

Family

ID=24354361

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18321/97A Abandoned AU1832197A (en) 1996-01-18 1997-01-17 Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts

Country Status (3)

Country Link
EP (1) EP0912187A2 (en)
AU (1) AU1832197A (en)
WO (1) WO1997025959A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843996A (en) * 1996-01-25 1998-12-01 Weglicki; William B. Intravenous magnesium gluconate for treatment of conditions caused by excessive oxidative stress due to free radical distribution
WO1998047497A2 (en) * 1997-04-23 1998-10-29 Fleming & Company, Pharmaceuticals Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
US20080317876A1 (en) 2007-05-18 2008-12-25 Saeed Sarkar Use of a magnesium isotope for treating hypoxia and a medicament comprising the same
EP1992339A1 (en) * 2007-05-18 2008-11-19 Saeed Sarkar Use of a magnesium isotope for treating hypoxia and a medicament comprising the same
DE102010039489A1 (en) * 2010-08-18 2012-02-23 Fresenius Medical Care Deutschland Gmbh concentrate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3350266A (en) * 1964-06-04 1967-10-31 Bristol Myers Co Antacid composition comprising aluminum hydroxide, magnesium hydroxide and magnesium gluconate
US3328304A (en) * 1964-07-31 1967-06-27 Guardian Chemical Corp Chelating agents and methods for their manufacture
US4962208A (en) * 1988-05-27 1990-10-09 Globus Alfred R Method for preparing time-stable solutions of non-pyrogenic magnesium gluconocitrates
US5002965A (en) * 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5108365A (en) * 1990-06-20 1992-04-28 Woods Jr Walter T Transluminal infusion of magnesium during coronary angioplasty
US5370989A (en) * 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
JP3003504B2 (en) * 1994-05-13 2000-01-31 ヘキスト・マリオン・ルセル株式会社 Electrolyte infusion

Also Published As

Publication number Publication date
WO1997025959A2 (en) 1997-07-24
EP0912187A2 (en) 1999-05-06
EP0912187A4 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
HUP0103920A3 (en) Methods and compositions for the prevention and treatment of anemia
AU2113295A (en) Novel compositions and methods for water treatment
AU3410195A (en) Method of inhibiting tissue ischemia and reperfusion injury
IL127664A (en) Compositions for the treatment and prevention of cachexia
AU1301295A (en) Biocidal compositions and methods for treating commercial and recreational water
AU9214398A (en) Compositions and methods for treating water
AU1751795A (en) Liposome compositions and methods for the treatment of atherosclerosis
AU1110192A (en) Method and composition for treating reperfusion injury
HUP0104410A3 (en) A composition for the prevention and/or treatment of atherosclerosis
EP1239855A4 (en) Method for the prevention and/or treatment of atherosclerosis
IL126696A0 (en) Azetidinone derivatives for the treatment of atherosclerosis
AU1509999A (en) Herbal drug composition for the prevention and treatment of dementia
AU2469599A (en) Methods for the prevention and treatment of fibrosis and sclerosis
AU1556497A (en) Agents for the treatment and prevention of aids
AU2821295A (en) Compositions and methods for the treatment of tumors
AU8588898A (en) Composition and process for the treatment of epidermal traumas such as decubitusulcers
AU1714697A (en) Method and composition for the treatment of osteoarthritis
AU4710401A (en) Method and composition for treatment of ischemic neuronal reperfusion injury
AU9226198A (en) The use of an nadph-oxidase inhibitor in the treatment of reperfusion injury
AU1832197A (en) Compositions and methods for the prevention and treatment of atherosclerosis and reperfusion injury with magnesium salts
AU4130597A (en) Use of essential fatty acids for the treatment and prevention of radiation damage to erythrocytes
AU1829097A (en) Methods for regenerating scarless skin and compositions used therein
AU2115197A (en) Compositions and methods useful in the detection and/or treatment of cancerous conditions
AU2750297A (en) Methods for prevention and/or treatment of neutropenia
HUP0102995A3 (en) Agents and method for the protective treatment of wood